Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Current Status of Pseudomonas aeruginosa Vaccine

Author(s): Lessandra Michelim, Gregory Saraiva Medeiros and Alexandre P. Zavascki

Volume 14, Issue 11, 2013

Page: [951 - 959] Pages: 9

DOI: 10.2174/1389201014666131226143923

Price: $65

Abstract

Pseudomonas aeruginosa is one of the major pathogens responsible for a wide variety of severe nosocomial and community acquired infections. Numerous vaccine candidates and several monoclonal antibodies have been developed over the past 40 years but only a few have reached clinical trials and none of these vaccine candidates has obtained market authorization. The understanding of P. aeruginosa pathogenesis and its virulence factors is essential in the identification of immunogens that can be used for a P. aeruginosa vaccine. This review summarizes the present status of vaccine development for this important pathogen.

Keywords: Cystic fibrosis, Clinical trials, Hospital infections, Immunity, Pseudomonas aeruginosa, Vaccines.


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy